Regeneus surges on back of Progenza patent news
Published 23-MAR-2020 12:13 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical-stage regenerative medicine company Regeneus Ltd (ASX: RGS) announced on Monday morning that the US Patent and Trademark Office (USPTO) had issued a notice of allowance for issuance of a new key patent for the company’s lead stem cell platform technology Progenza.
This paves the way for the issue of a patent that would be applicable in the US.
Highlighting what a major development this is for Regeneus, the group’s shares were up more than 10% despite the S&P/ASX All Ordinaries (XAO) being down more than 400 points.
This payment was made under the terms of a non-binding memorandum of understanding negotiated with Kyocera at the start of the month providing the latter with exclusive negotiation rights to the Progenza platform technology for the treatment of knee osteoarthritis in Japan.
The new patent to be granted in the US covers the treatment of inflammatory conditions with the combination of stem cells and secretions.
This includes inflammatory conditions caused by a wide range of diseases, such as arthritis, heart disease, autoimmune conditions, respiratory diseases, asthma, Crohn's disease and other gastrointestinal diseases.
Patent also covers Acute Respiratory Distress Syndrome
The patent to be granted for Progenza also covers Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition identified as a cause of death among patients diagnosed with COVID-19.
The success of Progenza on this front was recently documented in Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
ARDS is also a common cause of respiratory failure in critically ill patients.
Unlike pneumonia, there is no pharmaceutical treatment for ARDS23.
Notwithstanding the potential applications outside its core markets, Regeneus chief executive and executive director Leo Lee said, “While Regeneus’ focus remains on osteoarthritis and pain opportunities, this is a key patent which strengthens our intellectual property portfolio.
‘’It also opens doors to form partnerships for Progenza for other disease and indications.”
General Information Only
This material has been prepared by StocksDigital. StocksDigital is an authorised representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
